Cited source

Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis

Zhong Z, Xun Y, Shi X, et al. (2022)

Eur Arch Otorhinolaryngol · PMID 34415405

Abstract

OBJECTIVE: MP-AzeFlu is a novel option for therapy of allergic rhinitis (AR). The purpose of our study was to assess the safety and efficacy of MP-AzeFlu for the treatment of allergic rhinitis, compared to placebo and azelastine monotherapy. METHODS: The PubMed, MEDLINE, EMBASE and Cochrane databases were comprehensively searched for all published randomized controlled trials (RCTs) of using MP-AzeFlu nasal spray on July 26, 2019. In these studies, we selected patients with clinical symptom scores. The heterogeneity of the included studies was assessed by I2. RESULTS: Among the 336 citations retrieved, 6 articles with over 6000 patients were finally included in the meta-analysis. The results of meta-analysis revealed that MP-AzeFlu was superior to placebo (&#xa0;-&#xa0;2.43 [95%CI, &#xa0;-&#xa0;2.73 to &#xa0;-&#xa0;2.14], P&#x2009;<&#x2009;0.00001) and azelastine (&#xa0;-&#xa0;1.27 [95% CI, &#xa0;-&#xa0;1.57 to &#xa0;-&#xa0;0.97], P&#x2009;<&#x2009;0.00001) in reflective total nasal symptom score. In the MP-AzeFlu group, the instantaneous total nasal symptom score (&#xa0;-&#xa0;2.56 [95% CI, &#xa0;-&#xa0;3.02 to &#xa0;-&#xa0;2.10], P&#x2009;<&#x2009;0.00001) and the reflective total ocular symptom score (&#xa0;-&#xa0;1.22 [95% CI, &#xa0;-&#xa0;1.57 to &#xa0;-&#xa0;0.87], P&#x2009;<&#x2009;0.00001) were significantly reduced compared to the placebo group. CONCLUSION: MP-AzeFlu is as safe and mild as placebo and azelastine, which also is associated with symptom relief and the improvement of quality of life in AR patients. MP-AzeFlu can provide better clinical benefits than two currently available first-line intranasal therapies. It is an ideal therapy for AR patients.